Science Explorer Interactive view Map
Company · Xinghua · China

Regend Therapeutics (China)

regend.cnROR OpenAlex
World rank, 2022–2025
#12,334
of 28,054
Rank in China
#2,129
of 3,058
Research works
80
▲ 1151% vs 2013–17
Citations
916
11.4 per fractional work
Top-10% rate
19.0%
record average 16.5%
Open access
34%
world 28%

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.09× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.83× its world share, 16 worksBiochemistry, Geneti…Immunology and Microbiology: 9.12× its world share, 6 worksImmunology and Micro…Neuroscience: 2.18× its world share, 2 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 1.09× its world share, 0 worksPharmacology, Toxico…Chemistry: 1.18× its world share, 1 worksChemistryComputer Science: 0.04× its world share, 0 worksComputer ScienceEngineering: 0.19× its world share, 2 worksEngineeringMaterials Science: 0.35× its world share, 1 worksMaterials SciencePhysics and Astronomy: 0.02× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.10× its world share, 0 worksHealth ProfessionsMedicine: 2.79× its world share, 32 worksMedicinePsychology: 0.06× its world share, 0 worksPsychologySocial Sciences: 0.03× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.1×. Every wedge is a field page.

Which keywords describe research at Regend Therapeutics (China)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunotherapy, Tumor Regression, Cancer Immunotherapy, Lymphoma, CAR T Cells, Chimeric Antigen Receptor, Tumor Microenvironment and Cancer.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Immunotherapy12▲ 27×9 topics
  2. Cancer Immunotherapy10▲ 108×3 topics
  3. Tumor Regression10▲ 153×2 topics
  4. Lymphoma9▲ 94×2 topics
  5. CAR T Cells9▲ 196×1 topic
  6. Chimeric Antigen Receptor9▲ 196×1 topic
  7. Tumor Microenvironment5▲ 20×7 topics
  8. Cancer5▲ 6.4×17 topics
  9. Chemotherapy4▲ 9.6×7 topics
  10. Monoclonal Antibodies3▲ 56×2 topics
  11. Cancer Therapy3▲ 7.9×10 topics
  12. Regulation3▲ 8.3×4 topics
  13. Cell Proliferation3▲ 50×3 topics
  14. Transcriptional Regulation3▲ 27×7 topics
  15. Breast Cancer2▲ 17×3 topics
  16. Stem Cells2▲ 15×5 topics
  17. Immune Checkpoint Blockade2▲ 32×1 topic
  18. Mechanotransduction2▲ 53×2 topics
  19. PD-1 and PD-L12▲ 32×1 topic
  20. Clinical Outcomes2▲ 16×2 topics
  21. Hippo Pathway2▲ 249×1 topic
  22. Immunogenicity2▲ 76×2 topics
  23. Tumor Targeting2▲ 19×3 topics
  24. YAP/TAZ2▲ 249×1 topic
  25. Monoclonal Antibody2▲ 61×2 topics
  26. NK Cell Recognition2▲ 47×1 topic
  27. Natural Killer Cells2▲ 47×1 topic
  28. Bioanalytical Methods2▲ 150×1 topic
  29. Biosimilars2▲ 150×1 topic
  30. Cetuximab2▲ 35×2 topics
  31. Fluorouracil2▲ 89×1 topic
  32. Gene Therapy2▲ 16×4 topics
  33. Glycosylation2▲ 26×3 topics
  34. KRAS Mutations2▲ 89×1 topic
  35. Cancer Progression2▲ 15×6 topics
  36. Immunity2▲ 6.8×5 topics
  37. PET Imaging2▲ 17×4 topics
  38. Prognostic Factors2▲ 6.3×6 topics
  39. Metastatic2▲ 43×2 topics
  40. Trastuzumab2▲ 56×2 topics

Which research topics does Regend Therapeutics (China) publish most on?

By volume in 2022–2025: CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Hippo pathway signaling and YAP/TAZ and Immune Cell Function and Interaction.

CAR-T cell therapy resea…9CAR-T cell therapy research: 9 fractional worksCancer Immunotherapy and Biomarkers: 2 fractional worksHippo pathway signaling and YAP/TAZ: 2 fractional worksImmune Cell Function and Interaction: 2 fractional worksColorectal Cancer Treatments and Studies: 2 fractional worksBiosimilars and Bioanaly…2Biosimilars and Bioanalytical Methods: 2 fractional worksHER2/EGFR in Cancer Research: 2 fractional worksCancer Research and Treatments: 1 fractional worksImmunotherapy and Immune Responses: 1 fractional worksMultiple Myeloma Research and Treatments: 1 fractional works
OncologyCell BiologyImmunologyBiotechnology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 9 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 2 works
  3. 3 Hippo pathway signaling and YAP/TAZ Cell Biology 2 works
  4. 4 Immune Cell Function and Interaction Immunology 2 works
  5. 5 Colorectal Cancer Treatments and Studies Oncology 2 works
  6. 6 Biosimilars and Bioanalytical Methods Immunology 2 works
  7. 7 HER2/EGFR in Cancer Research Oncology 2 works
  8. 8 Cancer Research and Treatments Biotechnology 1 works
  9. 9 Immunotherapy and Immune Responses Immunology 1 works
  10. 10 Multiple Myeloma Research and Treatments Hematology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available34.0%not open66.0%

World: 28% of research is openly available.

with international co-authors22.9%domestic only77.1%

World: 19% is written across borders.

How has Regend Therapeutics (China)'s research output changed?

Output in 2018–2022 was 1151% higher than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.